Interleukin-33 antibody failed to demonstrate benefit in a phase II, double-blind, randomized, placebo-controlled study in adult patients with moderate-to-severe atopic dermatitis

Br J Dermatol. 2022 Oct;187(4):599-602. doi: 10.1111/bjd.21631. Epub 2022 Jul 29.

Authors

Affiliations

¹ First OC Dermatology, Fountain Valley, CA, USA.
² Área de Dermatología, National University of Cuyo, Mendoza, Argentina.
³ Department of Dermatology, University of Nice-Côte d'Azur, Nice, France.
⁴ Takagi Dermatological Clinic, Obihiro, Hokkaido, Japan.
⁵ Eli Lilly and Company, Indianapolis, IN, USA.

PMID: 35481678
DOI: 10.1111/bjd.21631

No abstract available

Publication types

Clinical Trial, Phase II
Letter
Randomized Controlled Trial

MeSH terms

Adult
Antibodies
Dermatitis, Atopic* / drug therapy
Double-Blind Method
Humans
Immunologic Tests
Interleukin-33

Substances

Antibodies
Interleukin-33